The lab instrument developer was crushed after a disappointing quarterly report. Investors are right to worry.
The titanium dioxide manufacturer performed well in the third quarter despite a challenging market environment.
The genetic-testing leader just whacked its fiscal full-year 2020 guidance.
Coal-fired power plants had a pretty bad summer, suggesting the record pace of retirements will continue for the foreseeable future.
Cities and countries around the globe are outlawing wasteful plastic products and promising to hold manufacturers accountable. That creates risks and opportunities for investors.
Investors are eager to see how Nerlynx is faring in light of a high discontinuation rate among patients and a recent label supplement that could reverse the trend.
It's an inevitable step in the evolution of healthcare -- and one that could help Illumina grow into its premium valuation.
The company, which has been built on opportunistic acquisitions, entered the final stretch of 2019 with a record level of cash to deploy.
It's difficult to believe, but Wall Street is worried that growth may be weakening.
The business is rolling heading into 2020, but Wall Street appears to be worried over something out of the company's control.
To rapidly decarbonize the global economy, wind and solar need some help. These two technologies could provide it.
The cancer-focused genetic testing service provider upgraded its offerings to provide higher-quality data from the same biological samples. That should keep growth humming along.
An excellent third-quarter performance for the genetic testing company has investors cheering.
Investors can't take the weakness in frack sand markets any longer, but the industrial segment is looking wobbly, too.
The animal-free protein developer announced solid third-quarter 2019 results and is now profitable, but investors wanted even more.
Fresh off an initial public offering, the pharmaceutical company has taken investors on a wild ride.
The lithium producer reduced full-year 2019 guidance and expects pricing pressure to remain in 2020, but better days are ahead.
The company's operations in New Mexico and Texas have been responsible for all earnings growth in 2019. Investors can thank the oil and gas industry.
The lithium producer cut 2019 guidance and told investors that they'll have to endure tough times into 2020.
At a time when other major lithium producers are slashing production growth plans, Livent is plowing full steam ahead. Wall Street hates the idea, but it could pay off.